SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1
Document Type: S-1
Date Filed: 2026-02-12
Accession Number: 0001493152-26-006407
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226006407/forms-1.htm

Chunk 66 of 83
Word Count: 1436
Character Count: 9426

Document Content:

holder. Pursuant to any applicable income tax treaty or other agreement, the IRS may make such report available to the tax authority in such non-U.S. holder’s country of residence. Dividends paid by us (or our paying agent) to a non-U.S. holder may also be subject to backup withholding at a current rate of 24%. Such information reporting and backup withholding requirements may be avoided, however, if such non-U.S. holder establishes an exemption by providing a properly executed, and applicable, IRS Form W-8, or otherwise establishes an exemption. Generally, such information reporting and backup withholding requirements will not apply to a non-U.S. holder where the transaction is effected outside the United States, through a non-U.S. office of a non-U.S. broker. Notwithstanding the foregoing, backup withholding and information reporting may apply, however, if the applicable withholding agent has actual knowledge, or reason to know, that such non-U.S. holder is a U.S. person.

Backup
withholding is not an additional tax; rather, the U.S. federal income tax liability of persons subject to backup withholding will be
reduced by the amount of tax withheld. If withholding results in an overpayment of taxes, a refund or credit may generally be obtained
from the IRS, provided that the required information is furnished to the IRS in a timely manner.

Foreign
Account Tax Compliance Act (FATCA)

Sections
1471 to 1474 of the Code, Treasury Regulations issued thereunder and related official IRS guidance, commonly referred to as FATCA, generally
impose a U.S. federal withholding tax of 30% on dividends on our common stock paid to a “foreign financial institution” (as
defined under FATCA, and which may include banks, traditional financial institutions, investment funds, and certain holding companies),
unless such institution enters into an agreement with the U.S. Department of the Treasury to, among other things, identify accounts held
by certain “specified United States persons” or “United States-owned foreign entities” (each as defined under
FATCA), report annually substantial information about such accounts, and withhold on certain payments to non-compliant foreign financial
institutions and certain other account holders. FATCA also generally imposes a U.S. federal withholding tax of 30% on dividends on our
common stock paid to a “non-financial foreign entity” (as specially defined under FATCA), unless such entity provides identifying
information regarding each of its direct or indirect “substantial United States owners” (as defined under FATCA), certifies
that it does not have any substantial United States owners, or otherwise establishes an exemption. Accordingly, the institution or entity
through which our common stock is held will affect the determination of whether such withholding is required.

The
withholding obligations under FATCA generally apply to dividends on our common stock. Such withholding will apply regardless of whether
the beneficial owner of the payment otherwise would be exempt from withholding pursuant to an applicable tax treaty with the United States,
the Code, or other exemptions described above. Under certain circumstances, a non-U.S. holder might be eligible for refunds or credits
of such taxes.

Under
proposed regulations, FATCA withholding on payments of gross proceeds has been eliminated. These proposed regulations are subject to
change.

intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this
section. Prospective investors are encouraged to consult with their own tax advisors regarding the application of FATCA withholding to
their investment in, and ownership and disposition of, our common stock.

The
preceding discussion of U.S. federal tax considerations is for general information only. It is not tax advice to investors in their particular
circumstances. Each prospective investor should consult its own tax advisor regarding the particular U.S. federal, state and local and
non-U.S. tax consequences of purchasing, holding and disposing of our common stock, including the consequences of any proposed change
in applicable laws.

UNDERWRITING

have entered into an underwriting agreement with The Benchmark Company, LLC, acting as the representative of the underwriters in this
offering (the “Representative”). Subject to the terms and conditions of the underwriting agreement, we have agreed to sell
to the underwriters named below, and the underwriters have agreed, severally and not jointly, to purchase from us the number of shares
of common stock set forth opposite each underwriter’s name in the following table at the initial public offering price less the
underwriting discounts set forth on the cover page of this prospectus:

Underwriter Number of Shares

The Benchmark Company, LLC

TOTAL

The
underwriters have committed to purchase all of the shares offered by us other than those shares covered by the over-allotment option
described below, if they purchase any shares. The obligations of the underwriters may be terminated upon the occurrence of certain events
specified in the underwriting agreement.

have agreed to indemnify the underwriters against specified liabilities, including liabilities under the Securities Act, or to contribute
to payments the underwriters may be required to make in respect of those liabilities.

The
underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal
matters by their counsel and other conditions contained in the underwriting agreement. The underwriters reserve the right to withdraw,
cancel or modify offers to the public and to reject orders in whole or in part.

Over-Allotment
Option

have granted the underwriters an option to purchase from us, at the initial public offering price less the underwriting discounts and
commissions, up to an additional         shares of our common stock, solely to cover over-allotments,
if any. The underwriters may exercise this option, one or more times in whole or in part, for our common stock, any time during the 30-day
period from the date of the closing of this offering.

Underwriting
Discount, Commissions and Expenses

The
following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters. These amounts are
shown assuming both no exercise and full exercise of the underwriters’ option to purchase additional shares of our common stock,
assuming an initial public offering price of $       per share, the midpoint of the estimated price range set forth on the cover
page of this prospectus.

Per Share Total Without Exercise of Over-Allotment Option Total With Exercise of Over Allotment Option

Initial public offering price $ $ $

Underwriting discounts and commissions (1) $ $ $

Proceeds to us, before expenses $ $ $

(1)	Represents
underwriting discounts equal to seven percent (7%) of the gross proceeds from sales of shares
of common stock in this offering.

The
Representative has advised us that the underwriters propose initially to offer the shares to the public at the initial public offering
price set forth on the cover page of this prospectus and to dealers at that price less a concession not in excess of $          per
share. After the initial public offering, the public offering price, concession and discount may be changed.

have agreed to pay the Representative a non-accountable expense allowance equal to one percent (1%) of the aggregate gross proceeds from
sales of shares of common stock in this offering (including any shares of common stock sold pursuant to the exercise of the underwriters’
over-allotment option).

have also agreed to reimburse the Representative for its out-of-pocket and accountable expenses in an amount not to exceed $150,000 and
background checks on our senior management and directors in an amount not to exceed $7,500.

Pursuant
to the engagement letter between us and the Representative, dated August 5, 2024 (the “Engagement Letter”), we have paid
the Representative a retainer of $10,000 upon signing of the Engagement Letter and subsequent payments of $10,000 on each month thereafter
for a period of five months from the date of the Engagement Letter, in each case to be applied against actual out-of-pocket expenses.
If the Engagement Letter is terminated or the proposed initial public offering does not occur, any retainer balance will be refunded
to the extent expenses were not actually incurred in accordance with FINRA Rule 5110(g)(4)(A).

estimate that the total expenses of this offering payable by us, excluding the total underwriting discount, will be approximately $       .

Discretionary
Accounts

The
underwriters do not intend to confirm sales of the shares offered hereby to any accounts over which they have discretionary authority.

Electronic
Distribution

prospectus in electronic format may be made available on the websites maintained by one or more of the underwriters or selling group
members, if any, participating in this offering. The Representative may allocate a number of shares to the underwriters and selling group
members, if any, for sale to their online brokerage account holders. Any such allocations for online distributions will be made by the
Representative on the same basis as other allocations.

Representative’s
Warrant